| Allergan, Inc. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120129906 | MODULATORS OF S1P RECEPTORS - The present invention relates to novel diphenylethyne derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 05-24-2012 |
| 20120129829 | NOVEL INDOLE MODULATORS OF S1P RECEPTORS - The present invention relates to novel indole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 05-24-2012 |
| 20120129814 | NOVEL PHOSPHONIC ACIDS AS S1P RECEPTOR MODULATORS - The present invention relates to novel phosphonic acids derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 05-24-2012 |
| 20120123537 | TISSUE EXPANDER WITH SELF-HEALING ANTERIOR SIDE - A tissue expander includes an elastomeric shell having an anterior inside surface and a posterior inside surface with a self-healing layer abutting only a portion of the anterior inside surface. The layer is spaced apart from the posterior inside surface while facilitating folding of the shell prior to insertion into a tissue pocket and also enabling inflation of the shell subsequent to insertion by a fluid injected between the self healing layer and posterior surface. | 05-17-2012 |
| 20120123196 | GASTRIC BAND DEVICES AND DRIVE SYSTEMS - Gastric banding devices, and drive systems designed to operate gastric banding devices, are disclosed. The gastric banding devices and drive systems intend to increase performance, durability, and simplicity over known gastric banding systems. Embodiments include transmission systems configured to output a variable force. Embodiments also include banding structures biased to apply a constrictive force to a patient's stomach. Supporting, or skeletal, structures are also disclosed. Various drive systems designed to improve power efficiency are also disclosed. | 05-17-2012 |
| 20120123095 | PROCESS AND SYSTEM FOR OBTAINING BOTULINUM NEUROTOXIN - Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use. | 05-17-2012 |
| 20120122989 | METHOD OF ENHANCING HAIR GROWTH - Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I | 05-17-2012 |
| 20120122945 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL - The present invention relates to novel compounds, ester pro-drugs of [3-(1-1H-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals in the treatment of conditions mediated by adrenergic receptors. | 05-17-2012 |
| 20120115792 | Method For The Treatment Of Infraorbital Dark Circles Using Botulinum Toxins - Infraorbital dark circles can be treated by administration of a botulinum toxin to a patient. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of an eye of a patient with infraorbital dark circles. | 05-10-2012 |
| 20120115205 | Botulinum Neurotoxin Serotype B Activatable Botulinum Neurotoxin Serotype Bs - The specification discloses modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located in the di-chain loop region; and method of producing modified Clostridial toxins comprising Clostridial toxin substrate cleavage site located within the di-chain loop region. | 05-10-2012 |
| 20120114703 | Botulinum Toxin Administration to Treat Various Conditions - Methods for treating conditions in an animal or human subject. The conditions may be pain, skeletal muscle conditions, smooth muscle conditions, glandular conditions and cosmetic conditions. The methods comprise the step of administering a | 05-10-2012 |
| 20120109080 | PUNCTURE RESISTANT COMPOSITE MATERIALS - A needle guard assembly includes a first composite guard and a second composite guard, each including an arrangement of puncture resistant members on a flexible substrate. The first composite guard and the second composite guard are positioned such that the arrangement of puncture resistant members of the second composite guard are misaligned with the arrangement of puncture resistant members of the first composite guard. The assembly further includes an intermediate layer disposed between and connecting the first composite guard with the second composite guard. | 05-03-2012 |
| 20120108921 | GASTRIC BANDING SYSTEM ADJUSTMENT BASED ON A SATIETY AGENT CONCENTRATION LEVEL - Methods and devices are provided for adjusting a gastric band to obtain a predetermined optimal expression of hormones. These hormones may be used to control appetite, metabolism and other weight control mechanisms. Ultimately, weight-loss efficacy is desired by tightening or loosening the gastric band based on hormone response. | 05-03-2012 |
| 20120108792 | PROCESS AND SYSTEM FOR OBTAINING BOTULINUM NEUROTOXIN - Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use. | 05-03-2012 |
| 20120101574 | IMPLANTABLE MATERIALS - A textured breast implant is provided which generally includes a fluid fillable elastomeric shell having a texture defined by struts, for example, hollow struts, defining interconnected open cells. Methods of making the texture include applying a silicone dispersion to a base material and removing the base material from the coating to form a silicone-based structure comprising struts defining interconnected open cells, said struts including internal surfaces defining cavities within the struts. The method may further include the step of contacting the silicone based structure having cavities with a silicone dispersion to cause the silicone to enter and fill the cavities. | 04-26-2012 |
| 20120101478 | Dual Cartridge Mixer Syringe - A dual cartridge mixer syringe includes a first cartridge for containing a first formulation, a second cartridge for containing a second formulation, a first plunger for displacing said first formulation from said first cartridge, and a second plunger for displacing said second formulation from said second cartridge. A mixing assembly is provided for receiving and commingling the first and second formulation in unequal proportions; and a needle assembly, in fluid communication with said mixing assembly, provides for ejecting the commingled first and second formulation. | 04-26-2012 |
| 20120095499 | UPPER STOMACH GASTRIC IMPLANTS - A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive devices do not autonomously change shape, but instead react within the stomach to induce satiety. The devices may provide slowed entry into the stomach, thus reducing the intake capacity. Additionally, the devices may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, to stimulate satiety-inducing nerves. Some devices combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the devices within a delivery tube and transorally advancing the devices through the esophagus to be deployed within the stomach. Removal of the devices occurs in the reverse. The implants are formed of materials that permit the implant to be compressed into a substantially linear transoral delivery configuration and that will resist degradation over a period of at least six months within the stomach | 04-19-2012 |
| 20120095497 | NON-INFLATABLE GASTRIC IMPLANTS AND SYSTEMS - A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive devices do not autonomously change shape, but instead react within the stomach to induce satiety. The devices may take up volume within the stomach, thus reducing the intake capacity. Additionally, the devices may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, or the greater and lesser curvatures in the middle of the stomach, to stimulate satiety-inducing nerves. Some devices may combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the devices within a delivery tube and transorally advancing the devices through the esophagus to be deployed within the stomach. Removal of the devices occurs in the reverse. | 04-19-2012 |
| 20120095496 | REACTIVE INTRAGASTRIC IMPLANT DEVICES - Transoral three-dimensionally orthogonal intragastric spring systems, devices, methods of operation and manufacture are provided. A transoral three-dimensionally orthogonal intragastric spring system and/or device (and related methods of manufacture and operation) may reduce obesity or weight by stimulating the stomach walls of the patient. The three-dimensionally orthogonal intragastric spring device may be a purely mechanical device comprising a flexible body which in response to an input force in one direction, may deform and cause a resultant displacement in an orthogonal direction, thereby exerting a pressure on the inner stomach walls of the patient. Alternatively, a three-dimensionally orthogonal intragastric spring device may include a variable size balloon configured to occupy volume in the patient's stomach, thereby reducing the amount of space in the patient's stomach. | 04-19-2012 |
| 20120095495 | SPACE-FILLING INTRAGASTRIC IMPLANTS WITH FLUID FLOW - A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive devices do not autonomously change shape, but instead react within the stomach to induce satiety. The devices may take up volume within the stomach, thus reducing the intake capacity. Additionally, the devices may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, to stimulate satiety-inducing nerves. Also, certain devices slow gastric emptying by blocking or otherwise impeding flow through the pyloric sphincter. A number of devices combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the devices within a delivery tube and transorally advancing the devices through the esophagus to be deployed within the stomach. Removal of the devices occurs in the reverse. | 04-19-2012 |
| 20120095494 | INTRAGASTRIC IMPLANTS WITH COLLAPSIBLE FRAMES - Transoral obesity treatment devices and related methods for operation thereof are described which occupy space within a stomach and/or stimulate the stomach wall. The transoral obesity treatment devices and related methods are intended to assist a patient in maintaining a healthy body weight. Features of the devices include insertion transorally and without invasive surgery, without associated patient risks of invasive surgery, and without substantial patient discomfort. The life span of these devices may be material-dependent upon long-term survivability within an acidic stomach, but is intended to last one year or longer. The devices have the capacity to vary in size and are desirably self-actuating in that they change shape and/or volume using internal motors or actuators. The changing character of the devices helps prevent the person's stomach from compensating for the implant, such as sometimes happens with static intragastric devices. | 04-19-2012 |
| 20120095493 | ELEVATING STOMACH STIMULATION DEVICE - The medical systems, apparatuses and uses thereof for treating obesity and/or obesity-related diseases are provided which relate to devices designed to stimulate an internal surface of the stomach such as the cardia. Features of the obesity treatment devices include insertion of said devices transorally and without invasive surgery, without associated patient risks of invasive surgery, and without substantial patient discomfort. The devices include flotation portions and cardia-stimulating portions, so that as the level of stomach contents rise, the devices will contact and stimulate the nerves in the cardia region of the stomach to induce satiety. The devices may have non-inflatable balls, be made of skinned foam, have ballast members such as a weighted ball or quantity of saline for orientation, and various combinations thereof. | 04-19-2012 |
| 20120095492 | VARIABLE SIZE INTRAGASTRIC IMPLANT DEVICES - Transoral obesity treatment devices and related methods for operation thereof are described which occupy space within a stomach and/or stimulate the stomach wall. The transoral obesity treatment devices and related methods are intended to assist a patient in maintaining a healthy body weight. Features of the devices include insertion transorally and without invasive surgery, without associated patient risks of invasive surgery, and without substantial patient discomfort. The life span of these devices may be material-dependent upon long-term survivability within an acidic stomach, but is intended to last one year or longer. The devices have the capacity to vary in size and are desirably self-actuating in that they change shape and/or volume using internal motors or actuators. The changing character of the devices helps prevent the person's stomach from compensating for the implant, such as sometimes happens with static intragastric devices. | 04-19-2012 |
| 20120095484 | ARTICULATED GASTRIC IMPLANT CLIP - Intragastric implant devices for obesity treatment are disclosed. The device is passive and does not autonomously change shape, but instead reacts to movement of the stomach to induce satiety. The device includes a series of connected, articulated clips that plicate the stomach wall nondestructively (no puncturing through the gastric wall) such that the overall volume of the stomach is reduced. Cam-shaped clamping surfaces prevent slippage of the stomach tissue from within the clips. Methods of implant are disclosed including delivering the device through a transoral delivery tube and advancing the device through the esophagus to be deployed within the stomach. Removal of the device occurs in the reverse. | 04-19-2012 |
| 20120095483 | ANCHORED NON-PIERCING DUODENAL SLEEVE AND DELIVERY SYSTEMS - An intragastric implant for obesity treatment is disclosed. The device delays digestion by providing a duodenal sleeve, and may also slows gastric emptying by limiting flow through the pyloric sphincter. The implant includes an elongated axially-compressible duodenal sleeve having a non-tissue-piercing anchor on a proximal end sized to lodge within the duodenal bulb. The anchor may have oppositely-directed anchoring flanges to resists migration in both directions. The sleeve may also have barbed ribs to resist proximal movement back up into the stomach. A method of implant includes collapsing/compressing the device and transorally advancing it through the esophagus to be deployed within the duodenum. A dissolvable jacket may constrain the implant for delivery and naturally dissolve upon implant. Removal of the implant may occur in the reverse. | 04-19-2012 |
| 20120095385 | INTRAGASTRIC IMPLANTS WITH DUODENAL ANCHORS - Intragastric fluid transfer devices and related methods for operation thereof are disclosed. The intragastric fluid transfer devices and related methods are intended to assist a patient in maintaining a healthy body weight by stimulating the inner stomach walls and/or the inner duodenum walls. Features of the intragastric fluid transfer device include insertion of the devices transorally and without invasive surgery, without associated patient risks of invasive surgery, and without substantial patient discomfort. The life span of these intragastric fluid transfer devices may be material-dependent upon long-term survivability within an acidic stomach, but is intended to last one year or longer. | 04-19-2012 |
| 20120095384 | STOMACH-SPANNING GASTRIC IMPLANTS - A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive implants do not autonomously change shape, but instead react within the stomach to induce satiety. The implants may take up volume within the stomach, thus reducing the digestive capacity. Additionally, the implants may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, to stimulate satiety-inducing nerves. Also, a number of implants slow gastric emptying by blocking or otherwise impeding flow through the pyloric sphincter. Other implants delay digestion by providing a duodenal sleeve. A number of implants combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the implants within a delivery tube and transorally advancing the implants through the esophagus to be deployed within the stomach. Removal of the implants occurs in the reverse. | 04-19-2012 |
| 20120095288 | SELF-ADJUSTING GASTRIC BAND - Generally described herein are automatic, self-adjusting, gastric banding systems and improvements thereof, that are capable of automatically relaxing and contracting in response to a large bolus passing through the area of a patient's stomach constricted by a gastric band. Alternatively, and/or in addition in one or more embodiments, the gastric banding systems described herein may also help prevent pouch dilatation and/or erosion. The apparatus and systems described herein aid in facilitating obesity control and/or treating obesity-related diseases while generally being non-invasive once implanted. Furthermore, certain embodiments of the self-adjusting gastric banding systems disclosed herein are automatically adjustable without complicated fluid control mechanisms, flow rate limiting devices, and/or valves. The automatic adjustments may also be made in response to other changes in the patient's esophageal-gastric junction, for example, in response to size, shape, and or location changes. | 04-19-2012 |
| 20120094359 | Novel System and Method of Anaerobic Fermentation - The present invention relates to growing anaerobic bacteria by measuring the reduction potential of a growth media at a start time and determining a grow time by correlating the start time reduction potential with said reduction coefficient to calculate when said second anaerobic fermentation system will reach a sufficiently low oxygen concentration to enable growth for an anaerobic bacteria, then adding the anaerobic bacteria to the growth media at a time no sooner than the grow time. | 04-19-2012 |
| 20120093827 | TREATMENT OF AUTOIMMUNE DISORDERS WITH A NEUROTOXIN - Methods of treating one or more autoimmune disorders include a step of administering a Clostridial neurotoxin, such as a | 04-19-2012 |
| 20120089172 | RE-SHAPING INTRAGASTRIC IMPLANTS - The present application provides implantable intragastric devices for the treatment of obesity. The intragastric devices advantageously act as a volume-occupying device, and is able to survive implantation in a patient's stomach for a year or longer. In addition, the intragastric devices may be configured to stimulate an inner stomach wall and/or temporarily block the pylorus to slow gastric emptying and/or be rotationally variant, thereby encouraging different stimulation points on the inner wall of the stomach and limiting the stomach's ability to adapt over long term implantation. The intragastric devices may reshape the stomach cavity, such as by pushing on opposite sides so as to “planarize” the stomach. For instance, the device may be an inflated disk, or an implantable loop or a springy coil that may be straightened for delivery/extraction yet assume the loop or coil shape upon implant. | 04-12-2012 |
| 20120089170 | INTRAGASTRIC BALLOON GEOMETRIES - The present application provides intragastric devices for the treatment of obesity. The intragastric devices advantageously act as a volume-occupying device, and is able to survive implantation in a patient's stomach for a year or longer. In addition, the intragastric devices may provide additional benefits. For example, the intragastric device may be configured to stimulate an inner stomach wall and/or temporarily block the pylorus to slow gastric emptying and/or be rotationally variant, thereby encouraging different stimulation points on the inner wall of the stomach and limiting the stomach's ability to adapt over long term implantation. | 04-12-2012 |
| 20120088962 | SELF-ADJUSTING GASTRIC BAND - Generally described herein are automatic, self-adjusting, gastric banding systems and improvements thereof, that are capable of automatically relaxing and contracting in response to a large bolus passing through the area of a patient's stomach constricted by a gastric band. Alternatively, and/or in addition in one or more embodiments, the gastric banding systems described herein may also help prevent pouch dilatation and/or erosion. The apparatus and systems described herein aid in facilitating obesity control and/or treating obesity-related diseases while generally being non-invasive once implanted. Furthermore, certain embodiments of the self-adjusting gastric banding systems disclosed herein are automatically adjustable without complicated fluid control mechanisms, flow rate limiting devices, and/or valves. The automatic adjustments may also be made in response to other changes in the patient's esophageal-gastric junction, for example, in response to size, shape, and or location changes. | 04-12-2012 |
| 20120088800 | 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS - The invention provides compounds represented by the formula (I), each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity: wherein: A, m, n, p, a, X, Y and Z are defined in the specification. These compounds are useful for treating a disease or condition selected from the group consisting of glaucoma, dry eye, angiogenesis and pulmonary edema. | 04-12-2012 |
| 20120088734 | Cyclosporin Analogs - Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions. | 04-12-2012 |
| 20120088714 | SYSTEM FOR STORAGE AND SUBSEQUENT HANDLING OF BOTULINUM TOXIN - A system and method for storage of botulinum toxin containing pharmaceutical compositions is herein disclosed. Particular aspects of the instant disclosure relate to vials having preferred internal geometries that provide optimized lyophilization, vacuum drying, storage, reconstitution and extraction of a botulinum toxin-containing pharmaceutical composition. | 04-12-2012 |
| 20120083650 | SYSTEMS AND METHODS FOR ADJUSTING GASTRIC BAND PRESSURE - The present invention provides for an obesity treatment system for use in conjunction with a gastric band suitable for laparoscopic placement around a stomach of a patient to create a stoma. The obesity treatment system may use real-time objective measurement and clinical data to provide an optimal gastric band adjustment for the patient. The obesity treatment system may include a pressure sensing device coupled to the gastric band, and configured to detect a maximum tolerable pressure, and a pressure changing device coupled to the gastric band, and configured to adjust the gastric band for asserting an optimal pressure against the stomach of the patient, the optimal pressure based on an optimal pressure percentage and the maximum tolerable pressure. | 04-05-2012 |
| 20120083508 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN - Disclosed herein is a pharmaceutical composition comprising a pain-relieving anticonvulsant and an alpha-2B receptor agonist. The composition is effective for treating chronic pain, and methods of treating chronic pain using the composition and the compounds comprising it are also disclosed. | 04-05-2012 |
| 20120078831 | BREAST IMPLANT SURGICAL DECISION SUPPORT SYSTEM AND METHOD - Computer-assisted planning of breast implant surgery apparatus and methods are provided which generally include an anatomical input module configured to receive anatomical information indicative of pre-implant anatomical properties of a patient's breast, a preference module configured to receive preference information indicative of a desired post-implant anatomical property of a patent's breast, a tissue expander selection module configured to receive the anatomical and the preference information, and, based at least in part on the anatomical and preference information, to output recommended expander information indicating at least one tissue expander from an available plurality of tissue expanders, and an implant selection module configured to receive the anatomical and the preference information, and, based at least in part on the anatomical and preference information, to output recommended implant recommendation information indicating at least one implant from an available plurality of implants. | 03-29-2012 |
| 20120077891 | POROGEN COMPOSITIONS, METHODS OF MAKING AND USES - Provided are porogen compositions and methods of using such porogen compositions in the manufacture of porous materials, for example, porous silicone elastomers. The porogens generally include comprising a core material and shell material different from the core material. The porogens can be used to form a scaffold for making a resulting porous elastomer when the scaffold is removed. | 03-29-2012 |
| 20120077858 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE - The present invention provides compounds, that are N-alkyl-2-(1-(5-substituted-2-(3-oxo-3-(trifluoromethylsulfonamido)propyl)benzyl)pyrrolidin-2-yl)oxazole-4-carboxamide wherein the 5 substituent is selected from the group consisting of halo and alkyloxy radicals. The compound may be represented by the following formula | 03-29-2012 |
| 20120077857 | INHIBITION OF INFLAMMATION BYSIMULTANEOUS BLOCKADE OF MULTIPLE PROSTANOID RECEPTORS - The present invention provides a method for treating inflammation in a patient in need thereof comprising administering to said patient an effective amount of a compound according to formula | 03-29-2012 |
| 20120077012 | POROUS MATERIALS, METHODS OF MAKING AND USES - The present specification discloses porous materials, methods of forming such porous materials, materials and devices comprising such porous materials, and methods of making such materials and devices. | 03-29-2012 |
| 20120077010 | POROUS MATERIALS, METHODS OF MAKING AND USES - The present specification discloses porous materials, methods of forming such porous materials, materials and devices comprising such porous materials, and methods of making such materials and devices. | 03-29-2012 |
| 20120071448 | S1P3 Receptor Inhibitors for Treating Conditions of the Eye - Disclosed herein are compositions and methods for treating conditions of the eye using S1P3 receptor inhibitors. | 03-22-2012 |
| 20120071437 | TUNABLE CROSSLINKED POLYSACCHARIDE COMPOSITIONS - The present specification generally relates to injectable dermal fillers including multifunctional polyethylene glycol-based crosslinking agents, hydrogel compositions comprising a matrix polymer crosslinked with such crosslinking agents, and methods of treating a soft tissue condition using such hydrogel compositions. | 03-22-2012 |
| 20120065141 | STABILIZED BIODEGRADABLE NEUROTOXIN IMPLANTS - Biodegradable neurotoxin implants and methods of making and using such implants are provided. Biodegradable neurotoxin implants include a neurotoxin, a biodegradable polymer component, and an acidity regulating component. The biodegradable polymer component is effective in controlling the release of the neurotoxin from the implant when the implant is located in a patient's body. The acidity regulating component is effective in maintaining a pH of the implant in a desired range that may be effective in stabilizing the neurotoxin as the implant biodegrades when the implant is located in a patient's body. In one embodiment, an implant includes a | 03-15-2012 |
| 20120064059 | FUSION PROTEINS - A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acids encoding the fusion proteins, methods of preparing same and uses thereof are also described. | 03-15-2012 |
| 20120059216 | REMOTELY ADJUSTABLE GASTRIC BANDING SYSTEM - A fluid reservoir for use in a remotely adjustable gastric banding system comprises a housing and a flexible reservoir pouch positioned within the housing. The flexible reservoir pouch is coupled to an inflatable portion of a gastric band via flexible tubing. A pump coupled to the flexible reservoir pouch facilitates filling and draining the inflatable portion of the gastric band. The pump may be located within or outside of the housing. A receiving coil may be coupled to the housing, and the receiving coil forms a loop around the housing. The receiving coil receives radio frequency signals to drive the pump. A circuit board may be disposed in the housing for driving the pump to move the fluid between the flexible reservoir pouch and the inflatable portion of the gastric band. A portion of the circuit board may be a flexible circuit board to allow the housing to flex. | 03-08-2012 |
| 20120058098 | NON-CYTOTOXIC PROTEIN CONJUGATES - The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a dynorphin Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are also described. | 03-08-2012 |
| 20120046674 | POWER REGULATED IMPLANT - An implantable pumping system for pumping a fluid in an implantable gastric banding system comprises a pump for pumping the fluid. A voltage source provides a pump voltage to the system, and a voltage control circuit increases or decreases the pump voltage. A pump driver applies the pump voltage to the pump at a phase and a frequency. The implantable pumping system comprises a sensor that monitors a parameter to facilitate adjusting at least one of the phase or the frequency to maintain a desired value of the parameter. The parameter is associated with at least one of the implantable pumping system or the implantable gastric banding system. A micro controller is configured to manipulate at least one of the phase or the frequency to maintain the desired value of the parameter. The sensor may comprise a temperature sensor, a pressure sensor, and/or a flow rate sensor. | 02-23-2012 |
| 20120046520 | PARE PIEZO POWER WITH ENERGY RECOVERY - The present invention generally relates to medical systems and apparatus and uses thereof for treating obesity and/or obesity-related diseases, and more specifically, relates to systems and methods for energy recovery in a laparoscopically-placed gastric banding system operably coupled to a piezo actuator. The energy recovery may be obtained utilizing an energy recovery device, such as an inductor, coupled to the piezo actuator. The energy recovery device may utilize two circuits to facilitate energy recovery, and the two circuits may include diodes with opposite orientations to control current flow. | 02-23-2012 |
| 20120046332 | COMPOSITIONS AND METHODS FOR TREATING CORNEAL HAZE - Disclosed herein are compositions and methods for treating corneal haze. Compositions and methods of use comprise therapeutically effective amounts of compounds that agonize the EP2 and/or EP4 receptor. Administration of the disclosed compounds can prevent and treat corneal haze development. | 02-23-2012 |
| 20120045420 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS - The present specification discloses compositions and methods of transplanting tissue useful for treating a soft tissue condition of an individual. | 02-23-2012 |
| 20120041555 | SILICONE IMPLANT WITH IMPRINTED TEXTURE - A procedure for making an implant having a textured silicone surface is disclosed. The method may include the steps of providing a conventional mandrel and applying a pre-formed, polymeric mesh sock to the mandrel. The sock is contacted with a silicone dispersion and the silicone dispersion is at least partially cured with the sock in contact therewith. The silicone dispersion is at least partially cured while the sock is in contact therewith and the sock is them removed, for example, by dissolution, to leave a textured elastomeric material useful as a component of a breast implant shell. | 02-16-2012 |
| 20120041258 | IMPLANTABLE ACCESS PORT SYSTEM - An implantable injection port for use with a gastric band for treating obesity and for attaching to a tissue of a patient is disclosed. The implantable injection port includes a base having an anchor opening, a gear coupled to the base and rotatable about a central axis, the gear having a plurality of gear teeth, an anchor coupled to the gear, and a top portion spaced apart from the base and having a plurality of top teeth that engage with the plurality of gear teeth. The top portion is rotatable causing rotation of the gear such that the rotation of the gear causes movement of the anchor through the anchor opening of the base and into the tissue of the patient. | 02-16-2012 |
| 20120041031 | METHOD OF ACTIVATING REGULATORY T CELLS WITH ALPHA-2B ADRENERGIC RECEPTOR AGONISTS - Disclosed herein is a method of upregulating regulatory T-cells, and treating diseases that would benefit from such upregulation, by administering an alpha 2 receptor agonist. | 02-16-2012 |
| 20120035235 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS - Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an α-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, both acute and chronic. | 02-09-2012 |
| 20120035148 | OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC CONDITIONS - Compositions, and methods of using such compositions, useful for placement, for example injection, into the interior of human or animal eyes are provided. Such compositions include a therapeutic component, such as one or more corticosteroids, a biocompatible polymeric component, and a solvent component. | 02-09-2012 |
| 20120034462 | HAIR-LIKE SHAPED HYDROGELS FOR SOFT TISSUE AUGMENTATION - Hair-like shaped crosslinked hydrogels and methods for preparing such crosslinked hydrogels and are provided. | 02-09-2012 |
| 20120022646 | PROSTHETIC DEVICE AND METHOD OF USING IN BREAST AUGMENTATION AND/OR BREAST RECONSTRUCTION - A method of using a biocompatible surgical knitted, silk scaffold device in a breast augmentation or in s breast reconstruction cosmetic or surgical procedure such as single-stage or two-stage breast reconstruction. In an aspect of the invention, the silk scaffold employs a knit pattern that substantially prevents unraveling and preserves the stability of the mesh or scaffold device, especially when the mesh or scaffold device is cut. An example scaffold device employs a knitted mesh including at least two yarns laid in a knit direction and engaging each other to define a plurality of nodes. The at least two yarns include a first yarn and a second yarn extending between and forming loops about two nodes. The second yarn has a higher tension at the two nodes than the first yarn. The second yarn substantially prevents the first yarn from moving at the two nodes and substantially prevents the knitted mesh from unraveling at the nodes. | 01-26-2012 |
| 20120022034 | METHODS FOR REDUCING OR NEOVASCULARIZATION OR EDEMA - Methods for reducing or preventing neovascularization or edema in the eye by implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer. | 01-26-2012 |
| 20120021991 | USE OF A BOTULINUM NEUROTOXIN TO ALLEVIATE VARIOUS DISORDERS - Methods for treating obsessions and compulsions by local administration of a Clostridial toxin. The obsessions or compulsions can be eye poking, body rocking, finger biting, counting, checking and related disorders treated by low dose, intramuscular administration of a botulinum toxin. | 01-26-2012 |
| 20120021969 | PROSTHETIC IMPLANT SHELL - Methods for improving ejaculate of a patient in need thereof are presented, more particularly, methods for increasing ejaculate volume/prostatic fluid to increase viability of sperm contained therein by administration of a neurotoxin to the prostate of the patient, are provided. | 01-26-2012 |
| 20120015978 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION - This invention provides well defined 6-alkyl or hydroxyalkyl- | 01-19-2012 |
| 20120010706 | NON-ROTATING IMPLANT ASSEMBLY AND BACKING PLATE THEREFOR - The present specification discloses a backing plate comprising a front surface and a back surface comprising a plurality of parallel ridges and grooves, and soft tissue implants comprising such backing plates. | 01-12-2012 |
| 20120004723 | PROSTHETIC DEVICE AND METHOD OF USING IN BREAST AUGMENTATION AND/OR BREAST RECONSTRUCTION - A method of using a biocompatible surgical knitted, silk scaffold device in a breast augmentation or in a breast reconstruction cosmetic or surgical procedure such as single-stage or two-stage breast reconstruction. In an aspect of the invention, the silk scaffold employs a knit pattern that substantially prevents unraveling and preserves the stability of the mesh or scaffold device, especially when the mesh or scaffold device is cut. An example scaffold device employs a knitted mesh including at least two yarns laid in a knit direction and engaging each other to define a plurality of nodes. The at least two yarns include a first yarn and a second yarn extending between and forming loops about two nodes. The second yarn has a higher tension at the two nodes than the first yarn. The second yarn substantially prevents the first yarn from moving at the two nodes and substantially prevents the knitted mesh from unraveling at the nodes. | 01-05-2012 |
| 20120004722 | DEGRADATION RESISTANT IMPLANTABLE MATERIALS AND METHODS - Methods are provided for making materials suitable for implantation in a mammal. The methods include the steps of providing a base material having a desirable surface topography, such as a polyurethane foam, contacting the base member with a silicone-based fluid material to form a coating, and allowing the coating to set to form a silicone-based structure suitable for implantation in a mammal. The base material may be removed from the coating. | 01-05-2012 |
| 20110319460 | KINASE INHIBITORS - The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. | 12-29-2011 |
| 20110319454 | DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY - The invention provides well defined compounds having FPRL-1 agonist or antagonist activity. As such, the compounds of the invention are useful for treating a variety of ocular disorders. | 12-29-2011 |
| 20110318303 | IL-10 AND METHODS OF TREATING OCULAR AND OTHER DISEASES - Disclosed herein TPV1 is a method of treating ocular and systemic conditions by administering IL-10 and TPV134R polypeptides. | 12-29-2011 |
| 20110313073 | FOAM-LIKE MATERIALS AND METHODS FOR PRODUCING SAME - Described herein are foam-like materials having substantially the same physical structure of polyurethane foams but with properties that can be tailored for a particular application. Methods of forming these foam-like materials are also described. | 12-22-2011 |
| 20110312986 | Composition and Method for Treating Overactive Bladder - The present specification discloses compounds, compositions including such compounds, kits including such compounds and compositions, and methods of treating an individual suffering from overactive bladder and/or diabetes by administering such compounds or compositions to an individual in need thereof. | 12-22-2011 |
| 20110312886 | TGF- AND METHODS OF TREATING OCULAR AND OTHER DISEASES - Disclosed herein is a method of treating ocular and systemic conditions by administering a TGF-β. | 12-22-2011 |
| 20110309541 | OPEN-CELL SURFACE FOAM MATERIALS - The present specification discloses open cell surface foam materials, methods of forming such foam materials, biocompatible implantable devices comprising such foam materials, and methods of making such biocompatible implantable devices. | 12-22-2011 |
| 20110306827 | NEEDLE GUARD TO PROTECT ACCESS PORT TUBING - An inflatable tissue expander, suitable for implantation in a breast, is provided. In addition, a needle guard assembly, suitable to protect tubing leading from an implantable access port, is provided. The needle guard assembly may include a first composite guard and a second composite guard, each composite guard including an arrangement of puncture resistant members and a flexible substrate having a first side on which the puncture resistant members are positioned. The needle guard assembly may comprise a sleeve extending over an end of the tube. | 12-15-2011 |
| 20110306826 | OVER MOLDED IMPLANTABLE DEVICE TO PROTECT TUBING FROM PUNCTURE - An implantable device used in a gastric band system includes an access port, a tube coupled to the access port, and a shielding device covering a portion of the tube. The shielding device is positioned adjacent to the access port and covers the end of the tube coupled to the access port. The shielding device is made from a puncture resistant material, to protect the tube from puncture by a misplaced syringe needle inserted by a physician. | 12-15-2011 |
| 20110306824 | REMOTELY ADJUSTABLE GASTRIC BANDING SYSTEM - An implantable system comprises a housing that includes a flexible reservoir. The flexible reservoir is coupled to an inflatable portion of a gastric band via a fluid inlet/outlet. The flexible reservoir contains a fluid and has an expanded configuration and a contracted configuration. An access port may be coupled to the flexible reservoir and/or the gastric band to facilitate filling and draining the reservoir and/or the gastric band. A movable wall is slidably positioned around the flexible reservoir to move the flexible reservoir between the expanded configuration and the contracted configuration to move the fluid into and out of the inflatable portion of the gastric band. A driving mechanism is positioned around the movable wall and is capable of changing the size of the movable wall to compress or expand the flexible reservoir. A motor, coupled to the driving mechanism, may actuate the driving mechanism. | 12-15-2011 |
| 20110306635 | PYRIDINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B AND /OR ALPHA 2C ADRENERGIC RECEPTORS - The invention relates specifically to the use of certain 4-[1-(1H-Imidazol-4-yl)-ethyl]-2,3-substituted pyridine compounds and pharmaceutical compositions thereof to treat disorders associated with selective subtype alpha 2 adrenergic receptor modulation. | 12-15-2011 |
| 20110305747 | COMBINATION OF DAPSONE WITH OTHER ANTI-ACNE AGENTS - A composition suitable for topical application that contains at least two active ingredients, one of these being dapsone and one selected from the group consisting of adapalene, tazarotene and treinion for the effective treatment of acne and other dermatological conditions. | 12-15-2011 |
| 20110301408 | MAGNETICALLY COUPLED IMPLANTABLE PUMP SYSTEM AND METHOD - A magnetically coupled, implantable pump system comprises an external controller and an implantable device. A non-implantable magnet in an external controller produces a magnetic field that couples the non-implantable magnet to a magnet in the implantable device. A non-implantable motor moves the non-implantable magnet in a rotational direction. When the non-implantable magnet moves in the rotational direction, a piston coupled to the magnet moves within the implantable device. As the piston moves, an amount of fluid from a reservoir in the implantable device moves out of the reservoir and into an inflatable portion of a gastric band. The implantable device may also move fluid out of the inflatable portion of the gastric band. | 12-08-2011 |
| 20110294893 | NON-ACIDIC CYCLOPENTANE HEPTANOIC ACID, 2-CYCLOALKYL OR ARYLALKYL DERIVATIVES AS THERAPEUTIC AGENTS - The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc. | 12-01-2011 |
| 20110294768 | Ophthalmic Suspension for Ocular Use - A gatifloxacin and prednisolone topical ophthalmic pharmaceutical compositions for prevention and treatment of ophthalmic bacterial infections and inflammatory conditions associated with pre-surgical and/or post surgical ocular surgeries. | 12-01-2011 |
| 20110294742 | DEGRADABLE CLOSTRIDIAL TOXINS - The specification discloses modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; polynucleotide molecules encoding modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; and method of producing modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain. | 12-01-2011 |
| 20110288639 | Inflatable prostheses and methods of making same - An inflatable tissue expander, suitable for implantation in a breast, is provided. The tissue expander includes a puncturable, self-sealing anterior portion forming a fillable cavity, and posterior portion that is puncture resistant. The anterior portion includes a silicone-based elastomer material having a mesh embedded therein. The posterior portion includes a first composite guard and a second composite guard, each composite guard including an arrangement of puncture resistant members and a flexible substrate having a first side on which the puncture resistant members are disposed in a spaced apart fashion. | 11-24-2011 |
| 20110288481 | MODULAR INJECTION DEVICE - A modular injection device for administration of dermal filler compositions is provided. The injection device may include a handheld injector unit including a drive unit, the drive unit configured to apply an extrusion force to a fluid; a control unit remote from the injector unit, the control unit configured to control the drive unit; and a cable configured to connect the control unit to the injector unit. | 11-24-2011 |
| 20110288301 | AZA-INDOLES AND RELATED COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY - The present invention provides compounds are disclosed herein having the formula: | 11-24-2011 |
| 20110288094 | 1-ARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY - Compounds of the formula | 11-24-2011 |
| 20110287517 | Degradable Clostridial Toxins - The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras. | 11-24-2011 |
| 20110282444 | POROUS MATERIALS, METHODS OF MAKING AND USES - The present specification discloses porous materials, methods of forming such porous materials, biocompatible implantable devices comprising such porous materials, and methods of making such biocompatible implantable devices. | 11-17-2011 |
| 20110282057 | AZA-INDOLES AND RELATED COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY - The present invention provides compounds are disclosed herein having the formula: | 11-17-2011 |
| 20110281822 | AROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHONATE (S1P) RECEPTOR ACTIVITY - Novel aromatic compounds which are useful as sphingosine-1-phosphate modulators and useful for treating a wide variety of disorders associated with modulation of sphingosine-1-phosphate receptors. | 11-17-2011 |
| 20110278755 | POROGEN COMPOSITIONS, METHOD OF MAKING AND USES - The present specification discloses porogen compositions comprising a core material and shell material, methods of making such porogen compositions, methods of forming such porous materials using such porogen compositions, biocompatible implantable devices comprising such porous materials, and methods of making such biocompatible implantable devices. | 11-17-2011 |
| 20110276135 | PROSTHETIC IMPLANT SHELL - A fluid-filled prosthetic implant having a shell comprising a matrix material and an additive distributed in the matrix material. The implant can be imaged in vivo using magnetic resonance imaging to more clearly reveal defects in the shell, relative to a implant having a shell without the additive material. | 11-10-2011 |
| 20110276134 | SILICONE IMPLANT WITH IMPRINTED TEXTURE - A procedure for manufacturing an implant having a textured silicone surface is disclosed. An example procedure includes forming a component having a silicone surface; pressing a plurality of polymer fibers at least partially into the silicone surface, before the silicone has completely cured; allowing the silicone to at least partially cure with the polymer fibers in the silicone surface; and after the silicone is at least partially cured, removing the polymer fibers from the silicone surface. | 11-10-2011 |
| 20110276133 | POROUS MATERIALS, METHODS OF MAKING AND USES - The present specification discloses porous materials, methods of forming such porous materials, biocompatible implantable devices comprising such porous materials, and methods of making such biocompatible implantable devices. | 11-10-2011 |
| 20110275692 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS - A compound comprising | 11-10-2011 |
| 20110275688 | KETOROLAC COMPOSITIONS FOR CORNEAL WOUND HEALING - The present invention is directed to an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose which promotes epithelial wound healing in a patient's cornea. | 11-10-2011 |
| 20110275677 | INDOLE COMPOUNDS BEARING ARYL OR HETEROARYL GROUPS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR BIOLOGICAL ACTIVITY - The invention provides well-defined aryl and/or heteroaryl substituted indoles that are useful as sphingosine-1-phosphate agonists or antagonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with modulation of sphingosine-1-phosphate receptors. | 11-10-2011 |
| 20110270392 | ALL-BARRIER ELASTOMERIC GEL-FILLED BREAST PROSTHESIS - An elastomeric gel-filled prosthetic implant having a shell made of a single gel barrier layer. The barrier layer is formed of a homogeneous silicone elastomer capable of sterically retarding permeation of the silicone gel through the shell and having a bleed rate that is less than about 40% of the bleed rate of current shells which use a sandwiched construction with an internal barrier layer. Further, the barrier layer shell is made of a material that exhibits a wet strength that is comparable to or greater than current shells. The silicone elastomer may be a polydimethyl siloxane, and the substituted chemical group is a diphenyl group with a minimum mole percent of at least 13%. The implant may be designed for breast reconstruction or augmentation such that the shell is accordingly shaped. The shell wall thickness is at least 0.254 mm (0.010 inches), and desirably about 0.456 mm (0.018 inches). The implant shell may be made by dip-forming, spray-forming, or rotational molding. The exterior may be smooth or textured. | 11-03-2011 |
| 20110270391 | INFLATABLE PROSTHESES AND METHODS OF MAKING SAME - An inflatable tissue expander or more permanent prosthesis, suitable for implantation in a breast, is provided. The tissue expander includes a puncturable, self-sealing anterior portion forming a fillable cavity, and posterior portion that is puncture resistant. The anterior portion includes a silicone-based elastomer material having a mesh embedded therein. The posterior portion includes a first composite guard and a second composite guard, each composite guard including an arrangement of puncture resistant members and a flexible substrate having a first side on which the puncture resistant members are disposed in a spaced apart fashion. | 11-03-2011 |
| 20110270131 | METHOD AND SYSTEM FOR DETERMINING THE PRESSURE OF A FLUID IN A SYRINGE, AN ACCESS PORT, A CATHETER, AND A GASTRIC BAND - A method and system for determining pressure in a syringe, and more specifically to a syringe pressure accessory which can be connected to a syringe to determine pressure in a syringe and a gastric band. The syringe pressure accessory can detect a pressure of a syringe and/or a gastric band and digitally display the pressure. The syringe pressure accessory can include a durable unit and a disposable unit. The disposable unit can be disposed of after a single use, while the durable unit can be reused with multiple disposable units. The syringe pressure accessory can also include a syringe attachment unit and one or more display units for a caretaker or a patient. The display unit can be wirelessly connected to the syringe attachment unit to display a pressure chart or the results of various analysis of the pressure data. Markers can be added to the pressure chart. | 11-03-2011 |
| 20110270028 | BIOCOMPATIBLE AND BIOSTABLE IMPLANTABLE MEDICAL DEVICE - The present invention is related to a biocompatible and biostable implantable medical device. The present invention can include an implantable medical device including an electro-mechanical component. The electro-mechanical component can be coated with various novel and nonobvious coating combinations designed to promote biocompatibility and biostability. | 11-03-2011 |
| 20110270027 | METHOD AND SYSTEM FOR DETERMINING THE PRESSURE OF A FLUID IN A SYRINGE, AN ACCESS PORT, A CATHETER, AND A GASTRIC BAND - A method and system for determining pressure in a syringe, and more specifically to a syringe pressure accessory which can be connected to a syringe to determine pressure in a syringe and a gastric band. The syringe pressure accessory can detect a pressure of a syringe and/or a gastric band and digitally display the pressure. The syringe pressure accessory can include a durable unit and a disposable unit. The disposable unit can be disposed of after a single use, while the durable unit can be reused with multiple disposable units. The syringe pressure accessory can also include a syringe attachment unit and one or more display units for a caretaker or a patient. The display unit can be wirelessly connected to the syringe attachment unit to display a pressure chart or the results of various analysis of the pressure data. Markers can be added to the pressure chart. | 11-03-2011 |
| 20110270025 | REMOTELY POWERED REMOTELY ADJUSTABLE GASTRIC BAND SYSTEM - A remotely adjustable remotely power gastric band system may include a control device, an implant electronic device, and an implantable gastric band. The control device may telemetrically power and communicate with the implant electronic device, which may be used for adjusting the diameter of the implantable gastric band. The implant electronic device may store the gastric band adjustment history records of a patient and regulate the power received from the control device. To improve transmission efficiency, the implant electronic device may adopt a double modulation scheme for communicating with the control device. Furthermore, the implant electronic device may detect and resolve motor blockage issues related to the implantable gastric band. | 11-03-2011 |
| 20110270024 | SELF-ADJUSTING GASTRIC BAND HAVING VARIOUS COMPLIANT COMPONENTS - In some embodiments, the present invention generally provides self-adjusting gastric banding systems for the treatment of obesity and obesity related conditions, as well as systems for allowing the automatic self-adjustment of gastric bands when a patient swallows a large bolus. In some embodiments, the present invention generally provides for gastric banding systems having a satiety booster, for example, to increase satiety levels when a patient desires to curb appetite at a particular time. In some embodiments, the present invention may provide for gastric banding systems that allow for both the automatic self-adjustment of gastric bands when a patient swallows a large bolus and an incorporated satiety booster for increasing satiety levels when a patient desires to curb appetite at a particular time. | 11-03-2011 |
| 20110270023 | IMPLANTABLE DEVICE TO PROTECT TUBING FROM PUNCTURE - An implantable device used in a gastric band system includes an access port, a tube coupled to the access port, and a shielding device covering a portion of the tube. The shielding device is positioned adjacent to the access port and covers the end of the tube coupled to the access port. The shielding device is made from a puncture resistant material, to protect the tube from puncture by a misplaced syringe needle inserted by a physician. | 11-03-2011 |
| 20110270022 | BIOCOMPATIBLE AND BIOSTABLE IMPLANTABLE MEDICAL DEVICE - The present invention is related to a biocompatible and biostable implantable medical device. The present invention can include an implantable medical device including an electro-mechanical component. The electro-mechanical component can be coated with various novel and nonobvious coating combinations designed to promote biocompatibility and biostability. One layer of the coating combinations can be a tie layer. Another layer of the coating combinations can be a layer formed on top of the tie layer, and having biocompatible and biostable properties. | 11-03-2011 |
| 20110270021 | ELECTRONICALLY ENHANCED ACCESS PORT FOR A FLUID FILLED IMPLANT - The present invention provides for an access port configured to detect its tilt within the body to facilitate a physician's access thereto. The access port can include a tilt detector to detect tilt datum, and a display screen to display the tilt of the access port. In addition, the tilt detector and the display screen can indicate whether the access port is flipped or not. The tilt detector can include an accelerometer to aid in determining the tilt of the access port. | 11-03-2011 |
| 20110270019 | IMPLANTABLE DEVICE TO PROTECT TUBING FROM PUNCTURE - An implantable device used in a gastric band system includes an access port, a tube coupled to the access port, and a shielding device covering a portion of the tube. The shielding device is positioned adjacent to the access port and covers the end of the tube coupled to the access port. The shielding device is made from a puncture resistant material, to protect the tube from puncture by a misplaced syringe needle inserted by a physician. | 11-03-2011 |
| 20110270018 | SELF-ADJUSTING MECHANICAL GASTRIC BAND - A self-adjusting gastric band applies a substantially constant force to a patient's fundus in order to facilitate weight control. The self-adjusting gastric band is capable of automatically relaxing and contracting in response to changes in the patient's fundus or in response to a large bolus passing through the patient's fundus that is constricted by the gastric band. The self-adjusting gastric band is automatically adjustable without hydraulic fluid and without external physician intervention. The self-adjusting gastric band comprises a movable member and a biasing mechanism coupled to the movable member to facilitate applying the substantially constant force against the fundus as the fundus changes size, shape and/or position. | 11-03-2011 |
| 20110270017 | SELF-ADJUSTING GASTRIC BAND HAVING VARIOUS COMPLIANT COMPONENTS - A self-adjusting gastric band is automatically adjustable without complicated fluid control mechanisms, flow rate limiting devices, and/or valves. The self-adjusting gastric band may automatically adjust to allow a large bolus of food to pass through a constriction in the patient's stomach formed by the gastric band. The self-adjusting gastric band comprises an inflatable portion that is disposable about an esophageal-gastric junction of the patient. A first compliant portion is coupled to the inflatable portion. The first compliant portion automatically relaxes the constriction formed by the self-adjusting gastric band and allows the large bolus to pass through the constriction. After the bolus passes through the constriction, the self-adjusting gastric band automatically returns to its previous state. | 11-03-2011 |
| 20110270016 | SELF-ADJUSTING GASTRIC BAND - A self-adjusting gastric band comprises an inflatable portion that includes a fluid such as saline. A reservoir is spaced from the inflatable portion according to a distance related to a wavelength of a peristaltic wave that propagates through the esophageal-gastric junction. A pressure-relief valve is coupled between the inflatable portion and the reservoir and allows an amount of the fluid to pass from the inflatable portion to the reservoir when a first force generates an increased pressure in the inflatable portion. The amount of fluid is released to allow the large bolus to pass through the esophageal-gastric junction. A contracted portion of the peristaltic wave is proximate the reservoir when an expanded portion of the wave is proximate the inflatable portion of the self-adjusting gastric band, to facilitate allowing the amount of the fluid to enter the reservoir. | 11-03-2011 |
| 20110269807 | NOVEL TREATMENT FOR AGE RELATED MACULAR DEGENERATION AND OCULAR ISCHEMIC DISEASE ASSOCIATED WITH COMPLEMENT ACTIVATION BY TARGETING 5-LIPOXYGENASE - The invention relates to compounds, compositions, drug delivery systems, and methods for treating age-related macular degeneration (AMD) and ocular ischemic disease in an individual in need. | 11-03-2011 |
| 20110263929 | SYSTEM AND METHOD FOR DETERMINING AN ADJUSTMENT TO A GASTRIC BAND BASED ON SATIETY STATE DATA AND WEIGHT LOSS DATA - A system and method for determining an adjustment to a gastric band, and more specifically to determining an adjustment to a gastric band based on satiety state data and weight loss data. The gastric band information system can determine an adjustment of the gastric band using a gastric band adjustment algorithm. The gastric band information system can wirelessly transmit the adjustment to the gastric band. The gastric band information system can receive gastric band data, weight data, glucose data, and/or blood pressure data and display a gastric band chart, a weight chart, and/or a blood pressure chart. The gastric band information system can also receive gastric band implantation data, patient data, and/or any other medical data. The various data can be received from a computer or medical devices in a wired or wireless manner. | 10-27-2011 |
| 20110263692 | THERAPEUTIC COMPOUNDS - A compound having a structure | 10-27-2011 |
| 20110263661 | 3-(4-((1H-IMIDAZOL-1-YL)METHYL)PHENYL)-5-ARYL-1,2,4-OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS - Substituted 3-(4-((1H-imidazol-1-yl)methyl)phenyl)-5-phenyl-1,2,4-oxadiazole derivatives which are useful as sphingosine-1-phosphate modulators and useful for treating a wide variety of disorders associated with modulation of sphingosine-1-phosphate receptors. | 10-27-2011 |
| 20110257761 | PROSTHETIC DEVICE HAVING REGIONS OF VARYING STRETCH AND METHOD OF MANUFACTURING THE SAME - A biocompatible surgical scaffold made from a multi-filament silk yarn for soft tissue reconstruction. The scaffold incorporates regions of varying stretch having different physical and mechanical properties that allow contouring to the required soft tissue shape to be replaced or repaired. The porous structure allows tissue in-growth, while the mesh degrades at a rate which allows for a smooth transfer of mechanical properties to the new tissue from the silk scaffold. | 10-20-2011 |
| 20110257743 | SOFT PROSTHETIC IMPLANT MANUFACTURING PROCESS - A soft prosthetic implant, for example, a breast implant, having a shell filled with a fluid. One or more components of the soft prosthetic implant receive a unique identifier for traceability during the manufacturing process. The unique identifier is placed on one component, such as a patch molded-in-place with a shell to form a soft prosthetic implant. Information about the respective components, as well as process parameters, can be stored on the unique identifier for later reference. The unique identifier may be a two-dimensional printed label or laser-etched characters, or may be a three-dimensional embossed or indented region. The unique identifier may be a separate label attached to the respective component, or may be formed in the component, such as with embossing. | 10-20-2011 |
| 20110257665 | PROSTHETIC DEVICE AND METHOD OF MANUFACTURING THE SAME - A biocompatible surgical silk mesh prosthetic device employs a knit pattern that substantially prevents unraveling and preserves the stability of the mesh device, especially when the mesh device is cut. An example prosthetic device employs a knitted mesh including at least two yarns laid in a knit direction and engaging each other to define a plurality of nodes. The at least two yarns include a first yarn and a second yarn extending between and forming loops about two nodes. The second yarn has a higher tension at the two nodes than the first yarn. the second yarn substantially prevents the first yarn from moving at the two nodes and substantially prevents the knitted mesh from unraveling at the nodes. | 10-20-2011 |
| 20110257238 | Heteroaryl Dihydroindolones as Kinase Inhibitors - The present invention provides a compound represented by the formula: | 10-20-2011 |
| 20110257232 | BIPHENYL OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE RECEPTORS MODULATORS - The present invention relates to novel biphenyl oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 10-20-2011 |
| 20110253251 | NEEDLE GUIDE - Needle guides are disclosed. An example needle guide includes a base; a housing configured to hold a container, the housing disposed on the base such that a longitudinal axis of the container is held at a first angle to vertical; and a syringe holder configured to guide insertion of a needle of a syringe into the container, the syringe holder disposed on the housing such that the syringe is inserted into the container at a second angle to the longitudinal axis of the container. | 10-20-2011 |
| 20110251453 | IMPLANTABLE COUPLING DEVICE - The present invention provides a system for attaching a fluid access port to a patient. The system generally comprises an implantable access port and method for attaching an access port to a patient. In addition, a tube guard, tube shroud, tissue guard, porous coupling member and a prefabricated mesh member may be attached to the access port. For example, the prefabricated mesh may be coupled to the access port to facilitate securing the access port to the tissue of the patient. | 10-13-2011 |
| 20110251285 | COMBINATIONS OF PRESERVATIVES FOR OPHTHALMIC COMPOSITIONS - The present invention provides a preservative composition for protecting ophthalmic solutions from microbial attack comprising a combination of benzalkonium ion and polyhexamethylene biguanide (PHMB) wherein the combined concentrations of benzalkonium ion and polyhexamethylene biguanide (PHMB) in said composition is sufficient to provide protection against microbial attack when said composition is added to an ophtalmic solution as compared to said ophthalmic soulution having the same concentration of benzalkonium ion and polyhexamethylene biguanide (PHMB), alone. | 10-13-2011 |
| 20110250294 | COMBINATIONS OF PRESERVATIVE COMPOSITIONS FOR OPHTHALMIC FORMULATIONS - The present invention provides a preservative composition for protecting ophthalmic solutions from microbial attack comprising a combination of benzalkonium ion and An oxy-chlorite moiety, e.g. purite wherein the combined concentrations of benzalkonium ion and An oxy-chlorite moiety, e.g. purite in said composition is sufficient to provide protection against microbial attack when said composition is added to an ophthalmic solution as compared to said ophthalmic solution having the same concentration of benzalkonium ion and An oxy-chlorite moiety, e.g. purite, alone. | 10-13-2011 |
| 20110245595 | METHODS OF DEPLOYING AN IMPLANTABLE INJECTION PORT - A surgical fastening system for implantable devices is disclosed. The implantable device may contain a plurality of fasteners in pre-deployment position, may have a housing fitted over or around fit which contains a plurality of fasteners in pre-deployment position, or may be a part of a two-part system into which it fits. Accordingly, the present invention also encompasses a deployment system or tool that optionally positions the implantable device, and which causes the fasteners to move into post-deployment position. The fasteners may be staples, metal loops, coils, springs or hooks formed of biocompatible materials, including shape memory alloys such as NiTi. | 10-06-2011 |
| 20110238175 | BREAST IMPLANT SELECTOR SYSTEMS - A breast implant selector system including a breast width selector for selecting breast width input information, a breast tissue type selector for selecting breast tissue type input information in response to breast width input information selected with the breast width selector, and an implant size selector for selecting implant size input information in response to the breast tissue type input information selected with the breast tissue type selector. A result indicator provides a result characterizing at least one suggested breast implant as a function of the input breast width, breast tissue type, and implant size input information. | 09-29-2011 |
| 20110237871 | CONTROLLER SUPPORT APPARATUS - An apparatus comprises a controller for remotely controlling an implantable device that is used to adjust a gastric band, and the controller transmits a telemetric signal to the implantable device. The apparatus further comprises a table that provides support for the controller. A rail is oriented in a first direction with respect to the table, and a tray is slidably coupled to the rail. The tray receives the controller, and the rail moves the tray and the controller in the first direction with respect to the table. The apparatus further comprises a roller coupled to the rail. The roller aids in moving the rail, the tray, and the controller in a second direction with respect to the table. The apparatus further comprises an attachment mechanism for securing the controller to the tray. The apparatus locates the controller in a desired location with respect to a patient. | 09-29-2011 |
| 20110237797 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS - Disclosed herein are compounds represented by the structural formula: | 09-29-2011 |
| 20110230964 | PROSTHETIC IMPLANT SHELL - A fluid-filled prosthetic implant having a shell comprising a matrix material and an additive distributed in the matrix material. | 09-22-2011 |
| 20110229574 | POLYSACCHARIDE AND PROTEIN-POLYSACCHARIDE CROSS-LINKED HYDROGELS FOR SOFT TISSUE AUGMENTATION - Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent. The present hyaluronic acid-based compositions have enhanced flow characteristics, hardness, and persistence compared to known hyaluronic acid-based compositions. Methods and processes of preparing such hyaluronic acid-based compositions are also provided. | 09-22-2011 |
| 20110224703 | PROSTHETIC DEVICE HAVING DIAGONAL YARNS AND METHOD OF MANUFACTURING THE SAME - A knitted scaffold comprising at least two silk yarns in a knit direction and a yarn member diagonal to the knit direction to thereby provide a knitted fabric or mesh for surgical use that can retain its shape and/or resist collapse when opposing forces are applied at an angle from the knit direction. The knitted scaffold may include at least two yarns laid in a knit direction and engaging each other to define a plurality of nodes. The at least two yarns can include a first yarn and a second yarn extending between and forming loops about two nodes. The second yarn has a higher tension at the two nodes than the first yarn. The second yarn substantially prevents the first yarn from moving at the two nodes and substantially prevents the knitted mesh from unraveling at the nodes. | 09-15-2011 |
| 20110223170 | KLK-13 ANTIBODY INHIBITOR FOR TREATING DRY EYE - Disclosed herein is a method of treating dry eye with a KLK-13 antibody. | 09-15-2011 |
| 20110218392 | IMPLANTABLE BOTTOM EXIT PORT - The present invention provides a system for attaching a fluid access port to a patient. The system generally comprises an implantable access port with a bottom exit port and method for attaching an access port to a patient. In addition, a tube guard, flexible tube exit port, tissue guard, and porous coupling member are disclosed. | 09-08-2011 |
| 20110213199 | IMPLANTABLE ACCESS PORT DEVICE AND ATTACHMENT SYSTEM - A system for attaching an access port to bodily tissue includes an access port assembly and including an access port having a generally central axis. The access port assembly further includes an attachment mechanism structured to enable the access port to be attached, for example, to an abdominal muscle of a patient. The delivery tool includes a handle having a generally longitudinal axis and a delivery head structured to engage the access port assembly, and an activation mechanism for enabling deployment of the attachment mechanism when the delivery head is so engaged with the access port assembly. The delivery tool is configured such that the longitudinal axis of the handle is spaced apart from the generally central axis of the access port when the delivery head is so engaged with the access port assembly. | 09-01-2011 |
| 20110212925 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY - The present invention relates to novel amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 09-01-2011 |
| 20110208229 | SOURCE RESERVOIR WITH POTENTIAL ENERGY FOR REMOTELY ADJUSTABLE GASTRIC BANDING SYSTEM - The present invention includes a source reservoir with potential energy for a system for facilitating obesity control. The system includes a remote transmitter, a gastric band including at least one inflatable portion for containing a fluid, at least one reservoir for containing the fluid, and a high precision pump unit in communication with the reservoir for controlling pressure within the inflatable portion. | 08-25-2011 |
| 20110208220 | PRESSURE SENSING GASTRIC BANDING SYSTEM - An implantable device monitors a pressure of fluid within an inflatable portion of a gastric band. The implantable device comprises a tube defining a lumen, and a pressure sensor positioned within at least one of the lumen or the tube. The pressure sensor is configured to sense the pressure of the fluid within the inflatable portion of the gastric band. The pressure sensor is also configured to transmit a pressure signal based on the pressure to a microcontroller, which transmits the pressure signal to a remote control device. The pressure sensor confers strain relief upon at least a portion of the tube, and the pressure sensor shields at least a portion of the tube from puncture by a needle. | 08-25-2011 |
| 20110207995 | INDUCTIVELY POWERED REMOTELY ADJUSTABLE GASTRIC BANDING SYSTEM - A power management system provides wireless power to operate components of a remotely adjustable gastric banding system. The power management system comprises an external power component transmitting power, and an implantable power management component receiving power and converting the power for use in powering one or more components of the remotely adjustable gastric banding system, such as a pump. The internal power management component and the external power component may be tunable. By utilizing the power management system, implantable batteries may be eliminated. | 08-25-2011 |
| 20110206731 | BOTULINUM TOXIN THERAPY FOR SKIN DISORDERS - Methods for treating skin disorders by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a skin disorder. | 08-25-2011 |
| 20110201875 | REMOTELY ADJUSTABLE GASTRIC BANDING SYSTEM - An implantable device comprises a reservoir that contains a fluid for filling an inflatable portion of a gastric band. A device is coupled to the reservoir and includes stored potential energy having a first state and a second state. The first state represents a higher level of potential energy and the second state represents a lower level of potential energy. The implantable device further comprises a filling valve coupled between the reservoir and the gastric band, and the filling valve is configured to be opened in response to a first telemetric signal. The stored potential energy decreases from the first state to the second state when the filling valve is open, and a filling amount of the fluid moves from the reservoir to the gastric band when the stored potential energy decreases from the first state to the second state. | 08-18-2011 |
| 20110201874 | REMOTELY ADJUSTABLE GASTRIC BANDING SYSTEM - An implantable device comprises a reservoir for holding a fluid and a sensor positioned between the gastric band and the reservoir. The sensor monitors a parameter of the fluid when filling and draining the inflatable portion of the gastric band. A first flow control device controls a flow of the fluid when filling and draining the inflatable portion of the gastric band. A pumping device moves the fluid into and out of the inflatable portion of the gastric band, and the pumping device is capable of being activated and deactivated using a telemetric signal received from a remote device. | 08-18-2011 |
| 20110201684 | EP2 Agonist from Non-Prostanoid Structures Designed as PGE2 Antagonists - A method of treating ocular hypertension, lowering intraocular pressure, pain or inflammation, comprising administering to a mammal a pharmaceutical composition of an EP | 08-18-2011 |
| 20110200639 | Botulinum toxin treatments of Depression - Methods for preventing or treating depression including a depression mediated by the thalamus. Depression, including a thalamically mediated depression, can be treated by peripheral administration of a | 08-18-2011 |
| 20110196489 | BIOCOMPATIBLE STRUCTURES AND COMPOSITIONS - Described herein are material compositions including various textures which when implanted in a mammal encourage an optimal biological response. | 08-11-2011 |
| 20110196488 | DEGRADATION RESISTANT IMPLANTABLE MATERIALS AND METHODS - Methods are provided for making materials suitable for implantation in a mammal. The methods include the steps of providing a base material having a desirable surface topography, such as a polyurethane foam, contacting the base member with a silicone-based fluid material to form a coating, and allowing the coating to set to form a silicone-based structure suitable for implantation in a mammal. The base material may be removed from the coating. | 08-11-2011 |
| 20110196394 | IMPLANTABLE INJECTION PORT - An implantable injection port facilitates filling and/or draining an inflatable portion of a gastric band. In an embodiment, the port comprises a movable cap that causes anchor wires to extend from anchor devices in order to implant the injection port in the tissue of a patient. In another embodiment, the port comprises a handle that rotates to implant curved anchors into the tissue of a patient. In yet another embodiment, a cap is configured to move towards a base of the port in order to cause the curved anchors to rotate into the tissue of a patient. The cap may also rotate with respect to the base in order to lock the cap and the anchors in position. Further, surfaces of the injection port may be textured to increase adhesiveness to the patient's tissue during installation and to facilitate simpler installation. | 08-11-2011 |
| 20110196313 | Extendable Plunger Rod for Medical Syringe - An extendible plunger rod for use with a syringe is provided. Example plunger rods may include an outer plunger rod with a proximal end and a distal end, the outer plunger rod having an inner cavity; an inner plunger rod, housed at least partially within the inner cavity of the outer plunger rod; a compression spring disposed within the inner cavity of the outer plunger rod and between the proximal end of the outer plunger rod, and the inner plunger rod, the compression spring configured to exert force tending to push the inner plunger rod in a direction distal to the outer plunger rod; and a locking mechanism, the locking mechanism configured to prevent movement of the inner plunger rod relative to the outer plunger rod while both the inner and outer plunger rods are depressed into a syringe body, until the outer plunger rod has been depressed at least a first predetermined distance into the syringe body. | 08-11-2011 |
| 20110196195 | IMPLANTABLE SUBCUTANEOUS ACCESS PORT - The present invention generally provides a gastric banding system, including an implantable access port having a substantially ellipsoid shape. The access port is pliable and smooth, to increase the comfort of the access port to the patient, and to increase the aesthetic effect of the access port. The ellipsoid shape provides a large needle penetrable surface area for the access port, and enhances the ability of a physician to detect the access port through tactile means. A mesh layer may be incorporated in the housing of the access port, to increase durability of the housing, and to promote the self-sealing properties of the housing. | 08-11-2011 |
| 20110190301 | SUBSTITUTED CYCLOPENTANES OR CYCLOPENTANONES AS THERAPEUTIC AGENTS - Therapeutic compounds, methods, and compositions are disclosed herein for treating glaucoma and baldness in mammals. The specific compounds are described herein and are modified prostaglandin derivates. | 08-04-2011 |
| 20110190286 | THERAPEUTICALLY ACTIVE CYCLOPENTANES - Disclosed herein are compounds having a formula: | 08-04-2011 |
| 20110189773 | SILK FIBROIN FIBER BUNDLES FOR MATRICES IN TISSUE ENGINEERING - The present invention provides a novel silk-fiber-based matrix having a wire-rope geometry for use in producing a ligament or tendon, particularly an anterior cruciate ligament, ex vivo for implantation into a recipient in need thereof. The invention further provides the novel silk-fiber-based matrix which is seeded with pluripotent cells that proliferate and differentiate on the matrix to form a ligament or tendon ex vivo. Also disclosed is a bioengineered ligament comprising the silk-fiber-based matrix seeded with pluripotent cells that proliferate and differentiate on the matrix to form the ligament or tendon. A method for producing a ligament or tendon ex vivo comprising the novel silk-fiber-based matrix is also disclosed. | 08-04-2011 |
| 20110189292 | DERMAL FILLERS COMPRISING SILK FIBROIN HYDROGELS AND USES THEREOF - The present specification provides compositions useful as dermal fillers and methods using such compositions to treat a condition of skin. | 08-04-2011 |
| 20110189162 | Modified Clostridial Toxins Comprising an Integrated Protease Cleavage Site-Binding Domain - The present specification discloses modified Clostridial toxins, compositions comprising an integrated protease cleavage site-binding domain, polynucleotide molecules encoding such modified Clostridial toxins and compositions comprising di-chain forms of such modified Clostridial toxins. | 08-04-2011 |
| 20110184531 | OPEN CELLED FOAMS, IMPLANTS INCLUDING THEM AND PROCESSES FOR MAKING SAME - Described herein are open celled foams including a matrix of interconnected spheres. Also described herein are methods of making open celled foams as well as making composite members with open celled foam coatings covering at least a portion of the composite member. The open celled foams described herein are silicone based materials and can be used to coat implants such as breast implants and function to encourage tissue ingrowth and reduce capsular formation. | 07-28-2011 |
| 20110184229 | LAPAROSCOPIC GASTRIC BAND WITH ACTIVE AGENTS - A gastric banding system is provided which generally includes a gastric band and an active agent, for example, a metabolic agent or satiety inducing agent. The band may be structured to contain the agent and permit controlled release of the agent to the patient while the band is positioned around the stomach. Methods for treating obesity are also provided which include positioning a gastric band on the stomach of a patient and administering a satiety inducing agent to the patient while the gastric band is positioned on the stomach. In one embodiment, the active agent may be contained in a reservoir and dispensed to a portion of the patient's body. | 07-28-2011 |
| 20110184227 | PROSTHETIC DEVICE AND METHOD OF MANUFACTURING THE SAME - An implantable device for use in tissue and ligament repair comprising at least one knitted section and at least one single continuous fiber traversing the at least one knitted section, the at least one single continuous fiber forming a plurality of traverses extending through the at least one knitted section. The implantable device may comprise at least one single continuous silk fiber. The implantable device is suitable for use in a variety or reconstructive or support applications such as breast reconstruction, mastoplexy, breast augmentation revision, breast augmentation support, standard breast augmentation, chest wall repair, organ support, body contouring, abdominoplasty, facial reconstruction, hernia repair, and pelvic floor repair. | 07-28-2011 |
| 20110184055 | THERAPEUTIC AGENTS FOR TREATMENT OF OCULAR HYPERTENSION - The invention provides well-defined amides for treating glaucoma and ocular hypertension. | 07-28-2011 |
| 20110178147 | COMPOSITIONS AND METHODS FOR CONTROLLING PUPIL DILATION - The disclosure provides a composition for controlling pupil dilation comprising about 0.001% to about 1.0% by weight of an alpha-adrenergic receptor antagonist selected from phentolamine, phentolamine mesylate, or a phentolamine salt; and at least one excipient selected from the group consisting of a buffer, tonicity agent, preservative, antioxidant, surfactant, solubilizer, cosolvent, and a combination thereof. A method of controlling pupil dilation in a subject in need thereof, comprising administering a therapeutically effective amount of the composition is also provided. | 07-21-2011 |
| 20110178145 | ALPHA-2 ADRENERGIC AGONIST HAVING LONG DURATION OFINTRAOCULAR PRESSURE-LOWERING EFFECT - The present invention provides a method of lowering intraocular pressure which comprises administering a therapeutically effective amount of a pharmaceutical composition comprising 4-bromo-5-(2-imidazolin-2-ylamino)benzimidazole, or a salt thereof to the affected eye of a patient, as a single dose, wherein the affected eye has an intraocular pressure less than the baseline intraocular pressure for at least eight (8) hours. | 07-21-2011 |
| 20110178144 | THERAPEUTIC COMPOUNDS - Disclosed herein is a compound having a structure | 07-21-2011 |
| 20110178143 | THERAPEUTIC COMPOUNDS - Disclosed herein is a compound having a structure | 07-21-2011 |
| 20110178084 | THERAPEUTIC COMPOUNDS - Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof are disclosed, wherein a dashed line represents the presence or absence of a bond; and, wherein Y, A, R, D, and n are as described. Methods, compositions, and medicaments related thereto are also disclosed. | 07-21-2011 |
| 20110177053 | NON-CYTOTOXIC PROTEIN CONJUGATES - The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are also described. | 07-21-2011 |
| 20110172502 | DIARY/PLANNER FOR BREAST SURGERY PREPARATION AND METHOD - A breast augmentation or reconstruction surgery diary/planner and method includes a binder including a information section, disposed in said binder, regarding what a patient needs to know regarding surgical risks a self assessment form, disposed in said binder, for completion by said patient in order to facilitate discussion between a surgeon and said patient; and a surgery consent section, disposed in said binder, with signature blocks for both said surgeon and said patient. | 07-14-2011 |
| 20110172435 | Treatment Of Inflammatory Bowel Disease - Disclosed herein is a method comprising administering a compound to a mammal suffering from an inflammatory bowel disease for the treatment of said disease, said compound having a structure according to Formula I | 07-14-2011 |
| 20110172299 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES - Disclosed herein are compounds represented by a formula: Therapeutic methods, compositions, and medicaments related thereto are also disclosed. | 07-14-2011 |
| 20110171453 | IMMUNONEUTRAL SILK-FIBER-BASED MEDICAL DEVICES - Silk is purified to eliminate immunogenic components (particularly sericin) and is used to form fabric that is used to form tissue-supporting prosthetic devices for implantation. The fabrics can carry functional groups, drugs, and other biological reagents. Applications include hernia repair, tissue wall reconstruction, and organ support, such as bladder slings. The silk fibers are arranged in parallel and, optionally, intertwined (e.g., twisted) to form a construct; sericin may be extracted at any point during the formation of the fabric, leaving a construct of silk fibroin fibers having excellent tensile strength and other mechanical properties. | 07-14-2011 |
| 20110171286 | HYALURONIC ACID COMPOSITIONS FOR DERMATOLOGICAL USE - The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations hyaluronic acid and at least one additional constituent selected from the group consisting of vitamin B, C and vitamin E, wherein the formulation exhibits greater stability than an HA gel formulation without the additional constituent. Methods for treating lines, wrinkles, fibroblast depletions, and scars with the disclosed composition are provided as well. | 07-14-2011 |
| 20110167602 | IMMUNONEUTRAL SILK-FIBER-BASED MEDICAL DEVICES - Silk is purified to eliminate immunogenic components (particularly sericin) and is used to form fabric that is used to form tissue-supporting prosthetic devices for implantation. The fabrics can carry functional groups, drugs, and other biological reagents. Applications include hernia repair, tissue wall reconstruction, and organ support, such as bladder slings. The silk fibers are arranged in parallel and, optionally, intertwined (e.g., twisted) to form a construct; sericin may be extracted at any point during the formation of the fabric, leaving a construct of silk fibroin fibers having excellent tensile strength and other mechanical properties. | 07-14-2011 |
| 20110166531 | SYRINGE - A syringe is disclosed. The syringe may include a syringe body with a fluid chamber, the syringe body having a distal end and a proximal end, with an extrusion opening at the proximal end; a dividing wall disposed within the fluid chamber, defining a first fluid chamber and a second fluid chamber, the first fluid chamber and the second fluid chamber in communication with the extrusion opening; a first plunger disposed in a distal end of the first chamber, the first plunger including a first locking mechanism configured to prevent the first plunger from sliding away from the proximal end of the syringe body, when the first plunger is in a first initial position and the second plunger is being depressed; and a second plunger disposed in a distal end of the second chamber, the second plunger including a second locking mechanism configured to prevent the second plunger from sliding away from the proximal end of the syringe body when the second plunger is in a second initial position and the first plunger is being depressed. | 07-07-2011 |
| 20110160617 | CLINICAL ASSESSMENT SCALES AND METHODS - Disclosed herein are scales for assessing lip fullness, severity of perioral lines at rest, severity of perioral lines at maximum contraction or oral commissures. The scales comprise rows or columns of photographs corresponding to different severity categories. Each scale may have a Kappa score of at least about 0.700 for intra-rater and inter-rater reliability. | 06-30-2011 |
| 20110160271 | KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAIN - The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac. | 06-30-2011 |
| 20110152797 | PROSTAGLANDINS AND ANALOGUES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE - The present invention relates to cyclopentane heptenoic acid-5-cis-2-(3α-hydroxy or lower alkyloxy-5-thienylpentyl)-3,5-dihydroxy, [1α, 2β, 3α, 5α] compounds, lower alkyl, hydroxyl lower alkyl and indole lower alkyl amides and esters thereof as potent ocular hypotensives that are particularly suited for the management of glaucoma. | 06-23-2011 |
| 20110152608 | FLOW CONTROL METHOD AND DEVICE - Apparatus and methods are provided comprising an implantable non-hydraulic ring that encircles and provides a controllable degree of constriction to an organ or duct and an external control that powers and controls operation of the ring. The ring includes a rigid dorsal periphery that maintains a constant exterior diameter, and a compliant constriction system that reduces intolerance phenomena. A high precision, energy efficient mechanical actuator is employed that is telemetrically powered and controlled, and maintains the ring at a selected diameter when the device is unpowered, even for extended periods. The actuator provides a reversible degree of constriction of the organ or duct, which is readily ascertainable without the need for radiographic imaging. Methods of use and implantation also are provided. | 06-23-2011 |
| 20110152376 | 7-[3,5-DIHYDROXY-2- (3-HYDROXY-5-PHENYL-PENT-1-ENYL)- CYCLOPENTYL]-N-ETHYL-HEPT-5-ENAMIDE (BIMATOPROST) IN CRYSTALLINE FORM II, METHODS FOR PREPARATION, AND METHODS FOR USE THEREOF - The present invention provides a new crystalline form of bimatoprost, designated as crystalline form II. This new crystalline form is the most stable form known to date of bimatoprost. Moreover, it has been found that bimatoprost crystalline form II is readily prepared from crystalline form I. | 06-23-2011 |
| 20110152241 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY - The present invention relates to novel cyclic amine and cycloalkyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 06-23-2011 |
| 20110152198 | PHARMACEUTICAL COMPOSITIONS CONTAINING BOTULINUM TOXIN - This invention relates to the use of a composition comprising a polysaccharide and a botulinum toxin for reducing a skin wrinkle. In some embodiments, the polysaccharide comprises disaccharides. In some embodiments, the average molecular weight of a disaccharide unit of the polysaccharide is between about 345 D and about 1,000 D. | 06-23-2011 |
| 20110150846 | COMPOSITIONS AND METHODS FOR TISSUE FILLING AND REGENERATION - Injectable compositions are provided which include both a living cellular component and a filler component conducive to cell growth. The compositions are capable of providing both immediate tissue filling and long term tissue regeneration. | 06-23-2011 |
| 20110144670 | FLOW CONTROL METHOD AND DEVICE - An arterio-venous graft ( | 06-16-2011 |
| 20110137286 | INJECTION DEVICE FOR SOFT-TISSUE AUGMENTATION FILLERS, BIOACTIVE AGENTS AND OTHER BIOCOMPATIBLE MATERIALS IN LIQUID OR GEL FORM - Described herein are injection devices capable of automatically injecting substances into the soft tissue of a patient. The devices can inject low to high viscosity materials at predetermined, user selected injection rates, allowing the operator more control than a traditional syringe. The devices can allow mixing of more than one substance and/or reconstitution of a solid substance for injection. The injection devices described herein can allow the operator to easily inject one or more low to high viscosity liquid or gel soft-tissue augmentation fillers, one or more drugs, one or more other biocompatible materials, or combinations thereof. | 06-09-2011 |
| 20110137260 | SLOTTED SYRINGE - A syringe is disclosed. The syringe may include a syringe body with a fluid chamber, the syringe body having a proximal end and a distal end, with an extrusion opening at the proximal end; a first slot formed in the syringe body, starting near the proximal end of the syringe body and ending near the distal end of the syringe body; a first sleeve covering the first slot; a thumb grip, the thumb grip including a first slot guide disposed in the first slot, the thumb grip shaped to slide from a first position near the distal end of the syringe body toward a second position near the proximal end of the syringe body; and a plunger disposed in the fluid chamber of the syringe body, the plunger configured to move towards the proximal end of the syringe body in response to pressure applied by a user to the thumb grip, the plunger including a first plunger slot guide disposed in the first slot. | 06-09-2011 |
| 20110137112 | GASTRIC BAND WITH ELECTRIC STIMULATION - Apparatus and methods for stimulating one or more nerves by incorporating a gastric band system and an electrical stimulation component. Stimulation electrodes on the gastric band may be used to stimulate the vagal nerve and/or splanchnic nerve, which may inhibit the patient's appetite and/or control obesity. The gastric band may have an inflatable member for adjusting a stoma size. The stimulation electrodes may be mounted on the inflatable member. The system may include a controller including a pressure sensor for monitoring the hydraulic pressure within the inflatable inner member and for controlling the stimulation component. | 06-09-2011 |
| 20110136884 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF - The invention provides methods for treating disorders associated with selective subtype modulation of alpha 2 adrenergic receptors. In particular, the invention provides methods employing well-defined N-[1-(2 and/or 3-substituted-phenyl)-alkyl]-(4,5-dihydro-1H-imidazol-2-yl)-amines and pharmaceutical compositions thereof to treat disorders associated with selective subtype alpha 2 adrenergic receptor modulation, such as ocular disorders, pain and central nervous system (CNS) motor disorders. | 06-09-2011 |
| 20110130439 | CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLALKENYL DERIVATIVES AS THERAPEUTIC AGENTS - A compound comprising | 06-02-2011 |
| 20110129531 | Dermal Fillers Comprising Silk Fibroin Hydrogels and Uses Thereof - The present specification provides compositions useful as dermal fillers and methods using such compositions to treat a condition of skin. | 06-02-2011 |
| 20110124737 | ENHANCED BIMATOPROST OPHTHALMIC SOLUTION - A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. | 05-26-2011 |
| 20110124736 | COMPOSITIONS AND METHODS FOR STIMULATING HAIR GROWTH - Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I | 05-26-2011 |
| 20110124121 | METHODS FOR PREDICTING WEIGHT LOSS SUCCESS - Methods and kits for predicting weight loss success are provided. The methods generally include the steps of selecting a patient or other person undergoing or considering undergoing a weight loss therapy, obtaining a measurement of one or more hormone responses of the person to caloric intake, and subsequently predicting success of a weight loss therapy based on the hormone response. | 05-26-2011 |
| 20110117267 | Soft Prosthesis Shell Texturing Method - A method of texturing a soft prosthetic implant shell, such as a silicone breast implant shell. A soft prosthetic implant with a textured external surface layer of silicone elastomer and having an open-cell structure is made by adhering and then dissolving round salt crystals. The resulting roughened surface has enhanced physical properties relative to surfaces formed with angular salt crystals. An implant having such a textured external surface layer is expected to help prevent capsular contraction, to help prevent scar formation, and to help in anchoring the implant within the body. | 05-19-2011 |
| 20110117182 | COMBINATION OF DAPSONE WITH OTHER ANTI-ACNE AGENTS - A composition suitable for topical application that contains at least two active ingredients, one of these being dapsone and one selected from the group consisting of adapalene, tazarotene and treinion for the effective treatment of acne and other dermatological conditions. | 05-19-2011 |
| 20110112198 | COMPOSITIONS FOR ENHANCING HAIR GROWTH - Methods and compositions for stimulating the growth of hair are disclosed wherein emulsions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I | 05-12-2011 |
| 20110112166 | THERAPEUTIC CYCLOPENTANE DERIVATIVES - Compounds comprising formula (I) or a pharmaceutically acceptable salt thereof, are disclosed, wherein B, Y, and A are as described in claims | 05-12-2011 |
| 20110111483 | Optimizing Expression of Active Botulinum Toxin Type E - Nucleic acid molecules that comprise modified open reading frames providing increased expression of the encoded active BoNT/E in a heterologous cell, expression constructs and cells comprising such nucleic acid molecules and methods useful for expressing the encoding active BoNT/E from such nucleic acid molecules, expression constructs and cells. | 05-12-2011 |
| 20110111479 | Botulinum Neurotoxin Serotype B Activatable Botulinum Neurotoxin Serotype Bs - The specification discloses modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins comprising a Clostridial toxin substrate cleavage site located in the di-chain loop region; and method of producing modified Clostridial toxins comprising Clostridial toxin substrate cleavage site located within the di-chain loop region. | 05-12-2011 |
| 20110105581 | OPHTHALMIC FORMULATIONS CONTAINING SUBSTITUTED GAMMA LACTAMS AND METHODS FOR USE THEREOF - The invention provides ophthalmic formulations containing well-defined substituted gamma lactams. The formulations described herein are useful in treating a variety of ocular diseases related to ocular hypertension, such as for example, glaucoma. | 05-05-2011 |
| 20110105567 | Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity - Disclosed herein are compounds represented by: therapeutic methods, compositions, and medicaments related thereto are also disclosed. | 05-05-2011 |
| 20110093069 | IMPLANTS AND METHDOS FOR MANUFACTURING SAME - Implantable prosthesis, components of prosthesis, and methods of making same are provided. The methods generally include the steps of providing an implant shell, applying a curable fluid composition to the shell to form a coating thereon and applying a particulate component to the composition. The composition is a mixture, for example, an emulsion, containing a silicone-based elastomer dispersion and droplets of a suspended leachable agent. After the elastomer is stabilized and cured, the particulate component and leachable agent are removed, resulting in an implantable member having a porous, open-cell surface texture designed to be effective in reducing incidence of capsular formation or contraction. | 04-21-2011 |
| 20110092916 | INJECTION DEVICE - An injection device includes a syringe having a body with a piston disposed therein with an open end along with a viscous fluid disposed in the body for injection by the piston. A needle assembly is provided which includes a cannula, for example a blunt tipped cannula, having a luer connection engageable with the syringe distal end with the luer connector including a hub. Mating engagement is provided by way of internal threads at the syringe distal end and external treads of a hub with a pitch sufficient to prevent detachment of the hub from the syringe distal end during ejection of the viscous fluid. In addition, a stepped cavity, disposed in the hub, further prevents detachment of the hub from the syringe distal end during ejection of the viscous fluid. | 04-21-2011 |
